CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Clostridium botulinum neurotoxin type A, free from complexing proteins

Clostridium botulinum neurotoxin type A, free from complexing proteins

Last Updated: June 12, 2009

Result type: Reports

Project Number: SR0192-000

Product Line: Reimbursement Review

Generic Name: Clostridium botulinum neurotoxin type A, free from complexing proteins

Brand Name: Xeomin

Manufacturer: Merz Pharmaceuticals GmbH

Therapeutic Area: Cervical Dystonia

Indications: Cervical Dystonia

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 16, 2009

Recommendation Type: List in a similar manner

Clostridium botulinum neurotoxin type A, free from complexing proteins

Files